Recombinant NY-ESO-1 Protein

Phase 1Biologic

RRoswell Park Cancer Institute

Recombinant NY-ESO-1 Protein is one of 52 biologic programs targeting Colorectal Cancer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Colorectal CancerActive, not recruiting

Advanced Head and Neck Squamous Cell CarcinomaActive, not recruiting

Colorectal CancerPhase 1

Active, not recruiting

Advanced Head and Neck Squamous Cell CarcinomaPreclinical

Active, not recruiting

Competition

Competitive Landscape

254 competitors in Colorectal Cancer

#DrugCompanyPhaseTrials

Camptosar

Pfizer

Phase 3

34 2

Opdivo

Bristol-Myers Squibb

Phase 3

25 3

Keytruda

Merck & Co.

Phase 3

25 4

Fudr

Pfizer

Phase 3

17 5

Decadron

AAspen Global Incorporated

Phase 3

7 6

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

4 7

Balstilimab

AAgenus Inc.

Phase 3

9 8

5-Fu

TToray Industries, Inc

Phase 3

4 9

BL-M07D1

SSichuan Baili Pharmaceutical Co., Ltd.

Phase 3

1 10

Calcium Levofolinate

FFujian Cancer Hospital

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

PreclinicalActive, not recruiting

Advanced Head and Neck Squamous Cell Carcinoma

NCT02955290

Q1 2029

Phase 1Active, not recruiting

Colorectal Cancer

NCT06011772

Clinical

Trials by Indication[1]

Lung Cancer1 trial

A Vaccine (CIMAvax-EGF) for the Prevention of Lung Cancer Development or Recurrence

Completed·RRoswell Park Cancer Institute·Phase 1·NCT04298606·20 enrolled

Melanoma1 trial

Vaccine Therapy in Treating Patients With Advanced Stage III-IV Melanoma

Terminated·RRoswell Park Cancer Institute·Phase 1·NCT01744171·10 enrolled

Primary Peritoneal Cancer1 trial

Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Withdrawn·RRoswell Park Cancer Institute·Phase 1·NCT02833506

Colorectal Cancer1 trial

A Phase 0 Study of EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer

Active, not recruiting·RRoswell Park Cancer Institute·Phase 1·NCT06011772·2 enrolled

Advanced Head and Neck Squamous Cell Carcinoma1 trial

A Phase I/II Basket Trial of the EGF Vaccine CIMAvax in Combination With Anti-PD1 Therapy in Patients With Advanced NSCLC or Squamous Head and Neck Cancer

Active, not recruiting·RRoswell Park Cancer Institute·Preclinical·NCT02955290·51 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Recombinant NY-ESO-1 Protein. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Recombinant NY-ESO-1 Protein compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Recombinant NY-ESO-1 Protein. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roswell Park Cancer Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: RRoswell Park Cancer Institute

Recombinant NY-ESO-1 Protein

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q1 2029

Trials by Indication[1]

Lung Cancer1 trial

Melanoma1 trial

Primary Peritoneal Cancer1 trial

Colorectal Cancer1 trial

Advanced Head and Neck Squamous Cell Carcinoma1 trial

References

Drug Info

Quick Facts

Related News